The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D

Journal of Chemical Neuroanatomy

Volumn 40, Issue 1, 2010, Pages 36-42

  Mori, F ^a   Perez Torres S ^b   De Caro, R ^c   Porzionato, A ^c   Macchi, V ^c   Beleta, J ^b   Gavalda A ^b   Palacios, J M ^d   Mengod, G ^a  

^a INST D INVESTIGACIONS B   (Spain)

^b R and D Centre ^*  (Spain)

^c UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^d BrainCo Biopharma   (Spain)

Author keywords

Dorsal vagal motor nucleus; In situ hybridization histochemistry; Nucleus of the solitary tract; PDE4B; PDE4D

Indexed keywords

CYCLIC AMP; MESSENGER RNA; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IVA; PHOSPHODIESTERASE IVB; PHOSPHODIESTERASE IVC; PHOSPHODIESTERASE IVD; UNCLASSIFIED DRUG;

ADULT; AGED; AREA POSTREMA; ARTICLE; BRAIN BLOOD VESSEL; BRAIN STEM; CELL HYBRIDIZATION; CELLULAR DISTRIBUTION; CHEMORECEPTOR; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GLIA CELL; HISTOCHEMISTRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; MALE; NERVE CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; SOLITARY TRACT NUCLEUS; VAGUS NERVE DORSAL NUCLEUS; VOMITING;

ADULT; AGED; AREA POSTREMA; BLOOD VESSELS; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IN SITU HYBRIDIZATION; ISOENZYMES; MALE; MIDDLE AGED; NEUROGLIA; NEURONS; REFLEX; RNA, MESSENGER; SOLITARY NUCLEUS; VAGUS NERVE; VOMITING;

EID: 77952554012     PISSN: 08910618     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchemneu.2010.03.004     Document Type: Article

References (75)

1. Aoki M., Fukunaga M., Sugimoto T., Hirano Y., Kobayashi M., Honda K., Yamada T. Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor. J. Pharmacol. Exp. Ther. 2001, 298:1142-1149.
2. Barad M., Bourtchouladze R., Winder D.G., Golan H., Kandel E. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:15020-15025.
3. Barnette M.S., Christensen S.B., Essayan D.M., Grous M., Prabhakar U., Rush J.A., Kagey-Sobotka A., Torphy T.J. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J. Pharmacol. Exp. Ther. 1998, 284:420-426.
4. Barnette M.S., Grous M., Cieslinski L.B., Burman M., Christensen S.B., Torphy T.J. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. J. Pharmacol. Exp. Ther. 1995, 273:1396-1402.
5. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 1995, 75:725-748.
6. Beavo J.A., Brunton L.L. Cyclic nucleotide research - still expanding after half a century. Nat. Rev. Mol. Cell Biol. 2002, 3:710-718.
7. Beavo J.A., Conti M., Heaslip R.J. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 1994, 46:399-405.
8. Bender A.T., Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 2006, 58:488-520.
9. Bertolino A., Crippa D., di Dio S., Fichte K., Musmeci G., Porro V., Rapisarda V., Sastre, Schratzer M. Rolipram versus imipramine in inpatients with major, " minor" or atypical depressive disorder: a double-blind double-dummy study aimed at testing a novel therapeutic approach. Int. Clin. Psychopharmacol. 1988, 3:245-253.
10. Bolger G.B. Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell Signal 1994, 6:851-859.
11. Bolger G.B., Rodgers L., Riggs M. Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases. Gene 1994, 149:237-244.
12. Borinson H.L., Wang S.C. Physiology and pharmacology of vomiting. Pharmacol. Rev. 1953, 5:193-230.
13. Braun N.N., Reutiman T.J., Lee S., Folsom T.D., Fatemi S.H. Expression of phosphodiesterase 4 is altered in the brains of subjects with autism. Neuroreport 2007, 18:1841-1844.
14. Bureau Y., Handa M., Zhu Y., Laliberte F., Moore C.S., Liu S., Huang Z., Macdonald D., Xu D.G., Robertson G.S. Neuroanatomical and pharmacological assessment of Fos expression induced in the rat brain by the phosphodiesterase-4 inhibitor 6-(4-pyridylmethyl)-8-(3-nitrophenyl) quinoline. Neuropharmacology 2006, 51:974-985.
15. Carpenter D.O., Briggs D.B., Knox A.P., Strominger N. Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides. J. Neurophysiol. 1988, 59:358-369.
16. Cherry J.A., Davis R.L. A mouse homolog of dunce, a gene important for learning and memory in Drosophila, is preferentially expressed in olfactory receptor neurons. J. Neurobiol. 1995, 28:102-113.
17. Cherry J.A., Davis R.L. Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement, and affect. J. Comp. Neurol. 1999, 407:287-301.
18. Cherry J.A., Pho V. Characterization of cAMP degradation by phosphodiesterases in the accessory olfactory system. Chem. Senses 2002, 27:643-652.
19. Chung K.F. Phosphodiesterase inhibitors in airways disease. Eur. J. Pharmacol. 2006, 533:110-117.
20. Compton C.H., Gubb J., Nieman R., Edelson J., Amit O., Bakst A., Ayres J.G., Creemers J.P., Schultze-Werninghaus G., Brambilla C., Barnes N.C. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001, 358:265-270.
21. Conti M., Jin S.L. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 1999, 63:1-38.
22. D'Sa C., Eisch A.J., Bolger G.B., Duman R.S. Differential expression and regulation of the cAMP-selective phosphodiesterase type 4A splice variants in rat brain by chronic antidepressant administration. Eur. J. Neurosci. 2005, 22:1463-1475.
23. Duplantier A.J., Biggers M.S., Chambers R.J., Cheng J.B., Cooper K., Damon D.B., Eggler J.F., Kraus K.G., Marfat A., Masamune H., Pillar J.S., Shirley J.T., Umland J.P., Watson J.W. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J. Med. Chem. 1996, 39:120-125.
24. Engels P., Abdel'Al S., Hulley P., Lubbert H. Brain distribution of four rat homologues of the Drosophila dunce cAMP phosphodiesterase. J. Neurosci. Res. 1995, 41:169-178.
25. Fatemi S.H., King D.P., Reutiman T.J., Folsom T.D., Laurence J.A., Lee S., Fan Y.T., Paciga S.A., Conti M., Menniti F.S. PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. Schizophr. Res. 2008, 101:36-49.
26. Fatemi S.H., Reutiman T.J., Folsom T.D., Lee S. Phosphodiesterase-4A expression is reduced in cerebella of patients with bipolar disorder. Psychiatr. Genet. 2008, 18:282-288.
27. Gale D.D., Landells L.J., Spina D., Miller A.J., Smith K., Nichols T., Rotshteyn Y., Tonelli A., Lacouture P., Burch R.M., Page C.P., O'Connor B.J. Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers. Br. J. Clin. Pharmacol. 2002, 54:478-484.
28. Ghavami A., Hirst W.D., Novak T.J. Selective phosphodiesterase (PDE)-4 inhibitors: a novel approach to treating memory deficit?. Drugs R D 2006, 7:63-71.
29. Giembycz M.A. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?. Drugs 2000, 59:193-212.
30. Giembycz M.A. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?. Br. J. Pharmacol. 2008, 155:288-290.
31. Gong B., Vitolo O.V., Trinchese F., Liu S., Shelanski M., Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J. Clin. Invest. 2004, 114:1624-1634.
32. Halene T.B., Siegel S.J. Antipsychotic-like properties of phosphodiesterase 4 inhibitors: evaluation of 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone (RO-20-1724) with auditory event-related potentials and prepulse inhibition of startle. J. Pharmacol. Exp. Ther. 2008, 326:230-239.
33. Harris A.L., Connell M.J., Ferguson E.W., Wallace A.M., Gordon R.J., Pagani E.D., Silver P.J. Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig. J. Pharmacol. Exp. Ther. 1989, 251:199-206.
34. Heaslip R.J., Evans D.Y. Emetic, central nervous system, and pulmonary activities of rolipram in the dog. Eur. J. Pharmacol. 1995, 286:281-290.
35. Hebenstreit G.F., Fellerer K., Fichte K., Fischer G., Geyer N., Meya U., Sastre, Schony W., Schratzer M., Soukop W. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsychiatry 1989, 22:156-160.
36. Houslay M.D. PDE4 cAMP-specific phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 2001, 69:249-315.
37. Houslay M.D., Milligan G. Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem. Sci. 1997, 22:217-224.
38. Houslay M.D., Sullivan M., Bolger G.B. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv. Pharmacol. 1998, 44:225-342.
39. Itoh T., Abe K., Tokumura M., Horiuchi M., Inoue O., Ibii N. Different regulation of adenylyl cyclase and rolipram-sensitive phosphodiesterase activity on the frontal cortex and hippocampus in learned helplessness rats. Brain Res. 2003, 991:142-149.
40. Iwahashi Y., Furuyama T., Tano Y., Ishimoto I., Shimomura Y., Inagaki S. Differential distribution of mRNA encoding cAMP-specific phosphodiesterase isoforms in the rat brain. Mol. Brain Res. 1996, 38:14-24.
41. Jacobitz S., McLaughlin M.M., Livi G.P., Burman M., Torphy T.J. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol. Pharmacol. 1996, 50:891-899.
42. Kanes S.J., Tokarczyk J., Siegel S.J., Bilker W., Abel T., Kelly M.P. Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience 2007, 144:239-246.
43. Lamontagne S., Meadows E., Luk P., Normandin D., Muise E., Boulet L., Pon D.J., Robichaud A., Robertson G.S., Metters K.M., Nantel F. Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res. 2001, 920:84-96.
44. Lipworth B.J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005, 365:167-175.
45. McPhee I., Cochran S., Houslay M.D. The novel long PDE4A10 cyclic AMP phosphodiesterase shows a pattern of expression within brain that is distinct from the long PDE4A5 and short PDE4A1 isoforms. Cell Signal 2001, 13:911-918.
46. Millar J.K., Mackie S., Clapcote S.J., Murdoch H., Pickard B.S., Christie S., Muir W.J., Blackwood D.H., Roder J.C., Houslay M.D., Porteous D.J. Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness. J. Physiol. 2007, 584:401-405.
47. Miller A.D., Leslie R.A. The area postrema and vomiting. Front Neuroendocrinol. 1994, 15:301-320.
48. Miller A.D., Ruggiero D.A. Emetic reflex arc revealed by expression of the immediate-early gene c-fos in the cat. J. Neurosci. 1994, 14:871-888.
49. Miró X., Pérez-Torres S., Puigdomènech P., Palacios J.M., Mengod G. Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization. Synapse 2002, 45:259-269.
50. O'Donnell J.M., Zhang H.T. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol. Sci. 2004, 25:158-163.
51. Parkes J.D., Thompson C., Brennan L., Gajraj N., Howcroft B., Ruiz J. Rolipram in Parkinson's disease. Adv. Neurol. 1984, 40:563-565.
52. Pérez-Torres S., Cortés R., Tolnay M., Probst A., Palacios J.M., Mengod G. Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization. Exp. Neurol. 2003, 182:322-334.
53. Pérez-Torres S., Miró X., Palacios J.M., Cortés R., Puigdomènech P., Mengod G. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J. Chem. Neuroanat. 2000, 20:349-374.
54. Porzionato A., Macchi V., Morsut L., Parenti A., De Caro R. Microvascular patterns in human medullary tegmentum at the level of the area postrema. J. Anat. 2005, 206:405-410.
55. Puurunen J., Lucke C., Schwabe U. Effect of the phosphodiesterase inhibitor 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711) on gastric secretion and gastric mucosal cyclic AMP. Naunyn Schmiedebergs Arch. Pharmacol. 1978, 304:69-75.
56. Rabe K.F., Bateman E.D., O'Donnell D., Witte S., Bredenbroker D., Bethke T.D. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005, 366:563-571.
57. Reyes-Irisarri E., Perez-Torres S., Miro X., Martinez E., Puigdomenech P., Palacios J.M., Mengod G. Differential distribution of PDE4B splice variant mRNAs in rat brain and the effects of systemic administration of LPS in their expression. Synapse 2008, 62:74-79.
58. Robichaud A., Savoie C., Stamatiou P.B., Lachance N., Jolicoeur P., Rasori R., Chan C.C. Assessing the emetic potential of PDE4 inhibitors in rats. Br. J. Pharmacol. 2002, 135:113-118.
59. Robichaud A., Stamatiou P.B., Jin S.L., Lachance N., Macdonald D., Laliberte F., Liu S., Huang Z., Conti M., Chan C.C. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest. 2002, 110:1045-1052.
60. Schneider H.H., Schmiechen R., Brezinski M., Seidler J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur. J. Pharmacol. 1986, 127:105-115.
61. Scott A.I., Perini A.F., Shering P.A., Whalley L.J. In-patient major depression: is rolipram as effective as amitriptyline?. Eur. J. Clin. Pharmacol. 1991, 40:127-129.
62. Siuciak J.A., Chapin D.S., McCarthy S.A., Martin A.N. Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme. Psychopharmacology (Berl.) 2007, 192:415-424.
63. Soderling S.H., Beavo J.A. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr. Opin. Cell Biol. 2000, 12:174-179.
64. Souness J.E., Griffin M., Maslen C., Ebsworth K., Scott L.C., Pollock K., Palfreyman M.N., Karlsson J.A. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br. J. Pharmacol. 1996, 118:649-658.
65. Souness J.E., Rao S. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 1997, 9:227-236.
66. Spina D. PDE4 inhibitors: current status. Br. J. Pharmacol. 2008, 155:308-315.
67. Suda S., Nibuya M., Ishiguro T., Suda H. Transcriptional and translational regulation of phosphodiesterase type IV isozymes in rat brain by electroconvulsive seizure and antidepressant drug treatment. J. Neurochem. 1998, 71:1554-1563.
68. Takahashi M., Terwilliger R., Lane C., Mezes P.S., Conti M., Duman R.S. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J. Neurosci. 1999, 19:610-618.
69. Tomiyama M., Palacios J.M., Cortés R., Vilaró M.T., Mengod G. Distribution of AMPA receptor subunit mRNAs in the human basal ganglia: an in situ hybridization study. Mol. Brain Res. 1997, 46:281-289.
70. Torphy T.J., Undem B.J. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax 1991, 46:512-523.
71. Vitolo O.V., Sant'Angelo A., Costanzo V., Battaglia F., Arancio O., Shelanski M. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:13217-13221.
72. Wachtel H. Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3′,5′-monophosphate phosphodiesterase inhibitors. Psychopharmacology (Berl.) 1982, 77:309-316.
73. Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology 1983, 22:267-272.
74. Wachtel H., Schneider H.H. Rolipram, a novel antidepressant drug, reverses the hypothermia and hypokinesia of monoamine-depleted mice by an action beyond postsynaptic monoamine receptors. Neuropharmacology 1986, 25:1119-1126.
75. Weisinger R.S., Denton D.A., Di Nicolantonio R., Hards D.K., McKinley M.J., Oldfield B., Osborne P.G. Subfornical organ lesion decreases sodium appetite in the sodium-depleted rat. Brain Res. 1990, 526:23-30.